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Introduction
Cardiac transplantation remains the only available “curative” therapy for end-stage heart failure. However, 
the average survival after surgery is fewer than 10 years due to immune-mediated allograft rejection and 
side effects of  immunosuppressive drugs (1). This provides the impetus to manipulate the immune system 
to achieve heart allograft tolerance (2).
Tregs are a subset of  T cells expressing the transcription factor FoxP3 and the surface molecules CD4 
and CD25 (3). In addition to maintaining self-tolerance (4), Tregs can recognize allogeneic MHC mole-
cules and inhibit allograft rejection through different mechanisms (5). Tregs are currently under intensive 
investigation as an adoptive cell–based therapy to prevent transplant rejection and treat autoimmune dis-
eases (6). Polyclonal Treg-based cell therapy approaches yielded promising early results for the prevention 
of  graft-versus-host disease (7) and for curing type 1 diabetes (8, 9). We have also completed 2 phase I/
II clinical trials, the ONE Study UK Treg Trial (NCT02129881) (10) and the Safety of  Regulatory T Cell 
Therapy in Liver Transplant Patients (NCT02166177) (11), which assessed the safety and feasibility of  
adoptive transfer of  ex vivo expanded polyclonal Tregs in renal and liver transplant patients (12–14).
Manipulation of  Tregs in vitro can enhance their beneficial therapeutic effect (15, 16). Recently, our 
group showed that murine Nox2-deficient Tregs have higher suppressive activity in vitro on CD4+ T effec-
tor cell (Teff) proliferation than WT Tregs; this was attributed to increased nuclear levels of  FoxP3 and 
NF-κB, which led to increased expression of  CD25, CTLA-4, CD39, and CD73, key molecules linked to 
Treg suppressive function (17). An increased potency of  Nox2-deficient Tregs was also manifest in vivo by 
reducing inflammation in a model of  angiotensin II–induced (ANGII-induced) cardiovascular remodeling.
Nox2 is a ROS-generating enzyme, deficiency of which increases suppression by Tregs in vitro 
and in an in vivo model of cardiac remodeling. As Tregs have emerged as a candidate therapy in 
autoimmunity and transplantation, we hypothesized that Nox2 deficiency in Tregs in recipient 
mice may improve outcomes in a heart transplant model. We generated a potentially novel B6129 
mouse model with Treg-targeted Nox2 deletion (Nox2fl/flFoxP3Cre+ mice) and transplanted with 
hearts from CB6F1 donors. As compared with those of littermate controls, Nox2fl/flFoxP3Cre+ mice 
had lower plasma levels of alloantibodies and troponin-I, reduced levels of IFN-γ in heart allograft 
homogenates, and diminished cardiomyocyte necrosis and allograft fibrosis. Single-cell analyses 
of allografts revealed higher absolute numbers of Tregs and lower CD8+ T cell infiltration in Nox2-
deficient recipients compared with Nox2-replete mice. Mechanistically, in addition to a greater 
suppression of CD8+CD25– T effector cell proliferation and IFN-γ production, Nox2-deficient Tregs 
expressed higher levels of CCR4 and CCR8, driving cell migration to allografts; this was associated 
with increased expression of miR-214-3p. These data indicate that Nox2 deletion in Tregs enhances 
their suppressive ability and migration to heart allografts. Therefore, Nox2 inhibition in Tregs may 
be a useful approach to improve their therapeutic efficacy.
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Having shown that Nox2 impairs Treg suppressive function (17), we hypothesized that targeting its 
deletion in FoxP3+ T cells of  recipient mice could improve heart allograft survival.
Results
Generation of  mice with Nox2 deletion in Tregs. To analyze the contribution of Nox2 in Tregs to allograft pro-
tection, mice with FoxP3-targeted Nox2 deletion (Nox2fl/flFoxP3Cre+ mice) were generated by crossing male 
B6129S-Tg(FoxP3eGFP/iCre)1aJbS/J mice (18) with female Nox2fl/fl mice (19) (Supplemental Figure 1A; 
supplemental material available online with this article; https://doi.org/10.1172/jci.insight.149301DS1). Nox-
2fl/flFoxP3Cre+ mice were confirmed to have Nox2 DNA recombination (Supplemental Figure 1B), and the 
EGFP+ cells in Nox2fl/flFoxP3Cre+ mice were 95% CD25+FoxP3+ (Figure 1A). Nox2fl/flFoxP3Cre+ mice also 
had lower Nox2 mRNA levels (Figure 1B) in lymph nodes and reduced Nox2 protein levels in CD4+FoxP3+ 
but not CD4+FoxP3– cells (Figure 1, C and D). Purified Tregs from Nox2fl/flFoxP3Cre+ mice did not increase 
ROS production after stimulation with anti-CD3ε and anti-CD28 antibodies, unlike cells from control Nox2fl/fl 
mice. In fact, after stimulation, Tregs from Nox2fl/flFoxP3Cre+ mice produced comparable ROS levels to Tregs 
from littermate controls treated with a Nox2 flavoprotein inhibitor, diphenyleneiodonium (Figure 1, E and F).
Under baseline conditions, Nox2fl/fl control and Nox2fl/flFoxP3Cre+ mice had similar numbers of  CD4+ 
and CD8+ cells in thymus, spleen, and mesenteric lymph nodes (Supplemental Figure 2, A–C), including 
naive (CD44–CD62L+ cells), effector memory (CD44+CD62L– cells), central memory (CD44+CD62L+ cells), 
Th17 (CD4+RorγT+ cells), and CD4+ Tregs (CD25+FoxP3+ cells); CD8+ Tregs (CD8+FoxP3+ cells); and 
CD4+CD8+s T cells (in thymus only). Nox2fl/flFoxP3Cre+ and control Nox2fl/fl mice had similar baseline heart 
and vascular function parameters (Supplemental Figure 2, D–F).
Nox2 deficiency in Tregs improves allograft outcome. Mice with FoxP3-targeted Nox2 deletion (Nox2fl/flFox-
P3Cre+ mice; H-2b) and littermate controls (Nox2fl/fl mice; H-2b) were transplanted with hearts from CB6F1 
mice (H-2b/d). Allografts transplanted into Nox2fl/flFoxP3Cre+ mice showed delayed rejection as compared with 
those transplanted into littermate controls (Figure 2A and Supplemental Videos 1 and 2), along with dimin-
ished cardiomyocyte necrosis (Supplemental Figure 3A) and myocardial fibrosis (Supplemental Figure 3B) 7 
and 100 days after surgery. To further confirm the relevance of Nox2 deletion in Tregs to the protection from 
heart allograft rejection, an animal model that more closely resembles the clinical setting was used. Recipient 
mice were treated with cyclosporin (30 mg/kg) for 10 days after heart transplantation. Both Nox2fl/fl and Nox-
2fl/flFoxP3Cre+ mice had increased allograft survival rates after cyclosporin treatment, but the Nox2fl/flFoxP-
3Cre+ mice showed a lower rate of rejection (Figure 2A).
Plasma troponin-I levels were lower in Nox2fl/flFoxP3Cre+ mice compared with littermate controls (Fig-
ure 2B) 7 days after transplantation. Plasma alloantibody levels were reduced in mice with Treg-targeted Nox2 
deficiency 7 and 100 days after transplantation (Figure 2, C and D), while the inflammatory mediators, CCL2, 
IL-10, and IL-6, in allograft homogenates (Supplemental Figure 3, C–E) and CCL1 and CCL22 mRNA levels in 
heart tissues (Supplemental Figure 3, F and G) were equivalent between the 2 groups of mice 7 days after surgery.
To evaluate the contribution of  Tregs to improved heart allograft outcome, the presence of  FoxP3+EG-
FP+ cells was first analyzed in hearts transplanted into B6129S-Tg(FoxP3eGFP/iCre)1aJbS/J mice. The 
number of  recipient FoxP3+EGFP+ Tregs in allografts started increasing 3 days after transplant, peaked at 
day 7, and then decreased by day 14 (Figure 2E). The increased number of  Tregs at day 7 coincided with 
the higher FoxP3+ Treg numbers and Treg/Teff  ratios observed in allografts transplanted in Nox2fl/flFoxP-
3Cre+ mice compared with controls Nox2fl/fl (Figure 2, F–H). The higher Treg number was associated with 
reduced CD8+ cells but not CD4+ T cells in the allografts (Figure 2, I and J). Moreover, Nox2fl/flFoxP3Cre+ 
mice had lower IFN-γ levels in heart homogenates than Nox2fl/fl mice 7 days after transplantation (Figure 
2K). The numbers of  CD4+, CD8+, and FoxP3+ Tregs in spleens were similar between Nox2fl/flFoxP3Cre+ 
and Nox2fl/fl mice (Supplemental Figure 4).
Therefore, Nox2 deficiency in Tregs improves heart transplant outcomes and prevents acute rejection 
through the reduction of  CD8+ cell infiltration and IFN-γ production in the allografts associated with a 
higher proportion of  Tregs.
Nox2-deficient Tregs exhibit higher suppression of  CD8+ T cell proliferation. We have previously shown that 
Nox2-deficient Tregs inhibit in vitro CD4+ T Teff  proliferation more efficiently than WT Tregs (17). To assess 
whether the reduced number of  CD8+ T cells in the transplanted hearts in Nox2fl/flFoxP3Cre+ recipient mice 
was due to a superior inhibitory function of  Nox2-deficient Tregs, we purified and cocultured CD4+CD25+ 
Tregs with CD8+CD25– Teffs. Tregs deficient in Nox2 inhibited CD8+ WT Teff  proliferation (Supplemental 
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Figure 5, A and B) more efficiently than WT Tregs (IC50 = 0.13 vs. IC50 = 0.41). Additionally, Nox-2–deficient 
Tregs abolished the production of  IFN-γ by CD8+ Teffs, whereas a dose-dependent decrease was observed 
using different ratios of  WT Tregs to WT Teffs (Supplemental Figure 5C). Therefore, Nox2–/– Tregs exhibit 
higher suppression of  CD8+ Teff  proliferation and IFN-γ production than WT Tregs.
Nox2 deficiency favors Treg migration and homing into heart allografts. A potential mechanism underlying the 
increased number of  recipient Tregs in allografts is augmented leukocyte trafficking. Chemokine receptors 
are essential for the initial phases of  leukocyte trafficking (20) and were first analyzed in WT and Nox2- 
deficient Tregs purified from spleen and lymph nodes. These cells were predominantly thymus-derived Tregs, 
as approximately 70% of them were neurophilin-1+ (Supplemental Figure 6). Of the 17 chemokine recep-
tors evaluated, 6 had enhanced mRNA levels in Nox2-deficient Tregs (Figure 3A). Among these, CCR4 is 
of  particular interest, as it has been described as a homing receptor for the heart (21). The protein levels 
of  CCR2, CCR4, CCR6, CCR7, CCR8, and CXCR4 were further investigated by multicolor flow cytom-
etry (Figure 3, B and C, and Supplemental Figure 7, A and B). Nox2-deficient Tregs showed higher CCR4 
and CCR8 expression than WT Tregs (Figure 3, B and C), along with a higher chemotactic index toward 
CCL22 and CCL1, respectively (Figure 3D). The difference in chemotaxis was abolished by preincubation 
of  Tregs with the inhibitor of  phosphoinositide 3-kinases (PI3Ks), Ly29002. PI3Ks are known downstream 
effectors of  chemokine receptor signaling (22). Nox2-deficient Tregs also showed higher F-actin assembly 
Figure 1. Generation of mice with Treg-targeted Nox2 deletion. (A) EGFP+ cells from lymph nodes of Nox2fl/flFoxP3Cre+ mice stained with CD25 and FoxP3 anti-
bodies. Plots are representative of 3 Nox2fl/flFoxP3Cre+ and 3 Nox2fl/fl mice. (B) Nox2 mRNA levels in lymph nodes (n = 3–6 per group). (C and D) Nox2 protein levels 
in CD4+FoxP3+ and CD4+FoxP3– cells, respectively (n = 6 per group). (E and F) ROS estimated by dihydroethidium (DHE) fluorescence in purified Tregs stimulated 
with anti-CD3 (4 μg/ml) and anti-CD28 (8 μg/ml) antibody (n = 4–7 per group). Representative histograms are shown in E, and mean data is displayed in F. The 
dashed line in F represents the MFI of Nox2fl/fl cells preincubated with the flavoprotein inhibitor diphenyleneiodonium (DPI; 10 μM) 30 minutes before stimuli. 
Data are shown as mean ± SEM. *P < 0.05 for indicated comparisons, Mann Whitney 2-tailed t test in B–D and Kruskal-Wallis followed by Dunn’s post test in F.
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following incubation with CCL1 and CCL22 (Figure 3, E and F). Of note, CCR2, CCR4, CCR7, CCR8, 
and CXCR4 protein levels in CD4+CD25–FoxP3– and CD8+CD25–FoxP3– Teffs were comparable between 
WT and Nox2-deficient mice (Supplemental Figure 7, C and D). To further confirm the superior migratory 
capacity of  Nox2-deficient Tregs in vivo, WT and Nox2-deficient Tregs (H-2b), stained in green and orange, 
respectively, were adoptively cotransferred into C57BL/6 mice transplanted with CB6F1 hearts (Figure 3G). 
Supporting the previous results, a greater number of  Nox2-deficient Tregs were recovered from the allografts 
as compared with WT Tregs (Figure 3H).
Chemokines mediate integrin activation via inside-out signaling and consequently induce adhesion of lym-
phocytes to ECs (23). Therefore, in addition to chemotaxis, an increase in numbers of Tregs in the allograft 
may also be influenced by their adherence to cardiac ECs. After stimulation with CCL22, Tregs deficient in 
Nox2 displayed higher binding in vitro to ICAM-1 than WT Tregs (Figure 3, I and J). Moreover, when WT 
and Nox2-deficient Tregs stained in contrasting color dyes were co-perfused over cardiac ECs, the Nox2-defi-
cient cells displayed higher adherence to ECs (Figure 3K). Taken together, our data suggest that Nox2 expres-
sion in Tregs negatively regulates their chemotaxis and EC adherence.
miR-214-3p drives increased CCR4 and CCR8 expression in Nox2-deficient Tregs. The intracellular mechanism by 
which Nox2 controls transcription of CCR4 and CCR8 in T cells was next investigated. Because miRNAs are 
important regulators of transcription and a previous study showed that miR-214 deficiency decreases CCR4 
expression in T cells (24), we assessed this as a possible mechanism. PCR analyses using primers for these miRs 
revealed that Nox2-deficient Tregs have higher expression of miR-214-3p but comparable levels of miR-214-5p 
to WT Tregs (Figure 4A and Supplemental Figure 8A). Accordingly, Jurkat T cells incubated with a specific 
Nox2 inhibitor, gp91ds-tat, had higher mRNA levels of CCR4 and CCR8 than those incubated with sc-tat pep-
tide control. This increase was prevented in cells transfected with a miR-214-3p inhibitor (Figure 4, B and C). 
Transfection of Jurkat T cells with miR-214-3p mimetic also increased CCR4 and CCR8 mRNA levels (Figure 
4, B and C), and cells treated with the Nox2 inhibitor showed higher miR 214-3p levels, which were reduced by 
transfection with the miR inhibitor (Supplemental Figure 8B). The incubation of Jurkat T cells with PEG-SOD 
and PEG-catalase also increased the levels of miR-214-3p as well as CCR4 and CCR8 mRNAs, indicating that 
the Nox2 effects were ROS dependent (Figure 4, D–F). We next cloned the 3′ untranslated region of mouse 
CCR4 and part of the coding region harboring binding sites for miR-214-3p in CCR4 and CCR8 mRNAs into 
a dual-luciferase reporter vector. Jurkat T cells transfected with the CCR4 constructs showed a higher lucifer-
ase signal in the presence of gp91ds-tat or the miR-214-3p mimetic (Figure 4, G and H), suggesting increased 
CCR4 mRNA stabilization. The assays using the CCR8 construct showed an increased signal in the presence 
of gp91ds-tat but not miR-214-3p mimetic, pointing to a possible distinct regulatory mechanism (Figure 4I).
Finally, we studied the expression of  mRNA for Nox2, FoxP3, and miR-214-3p in heart allografts 7 
days after transplantation. The expression of  mRNA for FoxP3 in the allografts directly correlated with the 
Treg counts (Figure 5A) and inversely correlated with the expression of  mRNA for Nox2 (Figure 5B). In 
agreement with the results presented in Figure 2, F and G, and Figure 4A, Nox2 mRNA expression inverse-
ly correlated with Treg counts and with miR-214-3p expression in the heart allografts (Figure 5, C and D).
Taken together, our results indicate that Nox2 deficiency in Tregs improves heart allograft outcomes 
due to a greater suppression of  CD8+ Teff  proliferation and IFN-γ production. Additionally, Nox2-deficient 
Tregs migrate more efficiently into the allografts due to their increased expression of  CCR4 and CCR8 
mRNAs mediated via miR-214-3p.
Discussion
The development of  improved methods to suppress allograft rejection is a major goal to enhance the effec-
tiveness of  the life-saving cardiac transplant therapy. Previous work, including early phase clinical studies, 
Figure 2. Heart allografts transplanted into Nox2fl/flFoxP3Cre+ mice have higher Treg infiltration and better outcomes. Nox2fl/flFoxP3Cre+ mice and littermate 
controls (Nox2fl/fl) were transplanted with hearts from CB6F1 mice. Mice transplanted with hearts from C57BL/6 mice were used as isograft controls. (A) Allograft 
survival curves. Some mice were treated daily with cyclosporin (30 mg/kg) s.c. for 10 days after transplantation (n = 4–5 per group). (B) Plasma troponin-I levels 7 
days after transplant. (C and D) Plasma alloantibodies 7 and 100 days after the transplant. Representative histograms in D show the data obtained 100 days after 
transplant. (n = 3–5 per group). (E) Plots represent data from 3 allografts per time evaluated. The nontransplanted group represents data from 3 native hearts of 
naive nontransplanted mice. (F and G) Representative plots of CD25+FoxP3+ cells within the CD4+ cell population (F) and cells/mg of heart allograft 7 days after 
transplant (G). (H) Treg/Teff ratios. (I and J) Presence of CD4+ and CD8+ cells in transplanted hearts. Representative plots are shown in I, and cells/mg tissue is 
shown in J. (K) IFN-γ levels in heart allograft homogenates 7 days after surgery. Data are shown as mean ± SEM. †P < 0.05, *P < 0.05 compared with Nox2fl/fl mice, 
Mantel-Cox test (A); *P < 0.05 for indicated comparisons in B and C, G and H, and J and K, using Kruskal-Wallis followed by Dunn’s post test (n = 3–5 per group).
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suggests that the administration of  Tregs may be one way to induce immune tolerance and improve allograft 
outcome (7, 11). We focused on the ROS-generating enzyme Nox2, as we have recently found it to reduce 
Treg suppression of  CD4+ Teff  proliferation (17) and thereby increase cardiovascular inflammatory respons-
es. Here, a potentially novel mouse model with Treg-specific deficiency of  Nox2 in the recipient showed 
improved allograft outcomes, which were accompanied by reduced cardiomyocyte necrosis, lower myocardial 
fibrosis, and diminished circulating levels of  alloantibodies. The mechanisms underlying these improved out-
comes were increased chemotaxis and adherence of  Tregs in the transplanted hearts as well as an enhanced 
suppression of  CD8+CD25– Teff  proliferation by Nox2-deficient CD4+CD25+ cells. Additionally, Nox2- 
deficient Tregs downregulated IFN-γ production in cultures with CD8+ Teff  cells, which could also have con-
tributed to increase survival of  the heart allografts (Supplemental Figure 9).
Nox2 was previously shown to be involved in leukocyte migration in distinct disease contexts and relat-
ed to different cell types, including ECs (25), platelets (26), and neutrophils (27). In the present study, we 
observed that Nox2 deficiency upregulates CCR4 expression in CD4+CD25+ Tregs, which favors their infil-
tration into heart allografts. The importance of  Treg chemotaxis toward CCR4 ligands in the context of  heart 
allograft survival has been corroborated by previous studies (28–30). Long-term allograft survival induced 
by treatment with tanshinol plus rapamycin was reversed by neutralizing the CCR4 ligand CCL22 (29). Fur-
thermore, Lee et al. (28) showed that upregulation of  CCR4 and Treg infiltration of  the transplant following 
combined anti-CD154 monoclonal antibody and donor-specific transfusion induced tolerance, which was not 
observed in CCR4-deficient recipients or in mice receiving anti-CD25 antibody treatment.
It is well known that CCR4 inside-out signaling activates the integrin CD11a, which adheres more to 
ICAM-1 expressed by antigen-presenting cells (APCs) and ECs (31, 32). In fact, we observed that Nox2-defi-
cient Tregs had enhanced binding to ICAM-1 in vitro after CCL22 stimulation as compared with WT Tregs. 
As a consequence, Tregs deficient of Nox2 had a higher adherence to cardiac ECs, facilitating migration into 
allografts; the possible increased interaction with APCs, reducing their capacity to provide costimulatory sig-
nals, could have contributed to a higher suppression of CD8+ Teff  proliferation. Corroborating the impor-
tance of integrin activation to heart allograft survival, Warren et al. (32) showed that anti-α4 integrin anti-
body reduced the number of Tregs in transplanted hearts, leading to impaired allograft survival. The increased 
CCR8 expression displayed by Nox2-deficient Tregs could also have contributed to enhanced chemotaxis to 
allografts and to the higher suppressive function. In support of this, Barsheshet et al. (33) showed that the sup-
pressive function of CD25+CD127lo Tregs in vitro is upregulated by expression of CCR8 and the presence of  
its ligand CCL1 (33). Nox2-deficient Tregs showed enhanced expression of mRNA for 6 different chemokine 
receptors, despite only CCR4 and CCR8 having corresponding increases in protein levels as compared with 
WT Tregs. These discrepancies could be due to internalization and degradation of chemokine receptors (22).
We further explored the intracellular mechanism through which Nox2 regulates CCR4 and CCR8 expression 
in T cells and found that miR-214-3p is enhanced in Nox2-deficient Tregs. Our data support an miR-dependent 
upregulation of target mRNA transcription or stabilization previously reported in the literature (34–36). Con-
sistently, hearts from miR-214–deficient mice displayed lower CCR4 expression compared with WT controls 
(24), indicating upregulation rather than reduction of mRNA levels. Additionally, Nox2 mRNA levels in heart 
allografts inversely correlated with miR-214-3p levels, Treg counts, and FoxP3 mRNA expression. Our results 
agree with those of a previous study showing an association between decreased expression of miR-214-3p and 
increased levels of alloantibodies and development of bronchiolitis obliterans syndrome following lung transplan-
tation (37). Additionally, murine heart allografts had lower levels of miR-214-3p compared with isografts (38).
The higher Treg infiltration in recipient mice with Treg-targeted Nox2 deletion was associated with lower 
necrosis and fibrosis of  heart allografts and with lower plasma levels of  troponin-I as early as 7 days after sur-
gery. Indeed, increased troponin-I levels correlated positively in patients with acute heart transplant rejection 
(39), which was also observed in the murine heterotopic heart transplant model used in this study.
Figure 3. Nox2-deficient Tregs express higher levels of CCR4 and CCR8 than WT Tregs driving migration into heart allografts. Tregs were purified from spleens 
and lymph nodes of Nox2-deficient Tregs (Nox2–/–) and WT mice and assessed for (A) mRNA levels of chemokine receptors (n = 12); (B and C) CCR4 and CCR8 
protein levels by flow cytometry (n = 6); (D) chemotaxis in vitro toward CCL1 and CCL22; and (E and F) actin polymerization stimulated by CCL1 and CCL22. Some 
cells were incubated with Ly294002 (5 μM). Full minus one (FMO) antibody was used as a negative control. Graphs and images represent 1 of 3 independent 
experiments. Scale bar: 32 μm. (G, H, and K) WT and Nox2–/– Tregs were stained with different color cell tracers and tested for infiltration (after adoptive transfer) 
into CB6F1 hearts transplanted in C57BL/6 recipients (n = 4) (G and H) or adherence on cardiac ECs (K). (I and J) In vitro activation and binding of ICAM-1 in Tregs. 
Histograms and mean data represent 1 of 2 independent experiments. Data are shown as mean ± SEM. *P < 0.05 for indicated comparisons, Mann-Whitney  
2-tailed t test in C, H, and K; Kruskal-Wallis followed by Dunn’s post test in D and E; and 2-way ANOVA followed by Bonferroni’s post test in J.
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The lower interstitial fibrosis observed in allografts transplanted into recipient mice with Nox2 deletion 
agrees with our recent published data showing that the adoptive transfer of  Nox2-deficient Tregs induced low-
er cardiac fibrosis in a model of  ANGII-induced cardiovascular remodeling (17). It also agrees with findings 
from another study showing Treg depletion using anti-CD25 antibody aggravated cardiac fibrosis in a model 
of  virus-induced myocarditis, whereas adoptive transfer of  Tregs prevented it (40).
In addition to impaired T cell mediated alloresponses, there was a significant decrease in levels of  allo-
antibodies in mice with Nox2 deficiency in Tregs as compared with controls with preserved Nox2 activity. 
Because posttransplantation-reactive anti-HLA antibodies in humans are associated with the development, 
frequency, and severity of  cardiac allograft vasculopathy, it would be of  interest to assess whether Nox2 defi-
ciency in Tregs also affects this serious complication after heart transplantation (41).
Figure 4. miR-214-3p is upregulated in 
Nox2–/– Tregs and controls CCR4 and 
CCR8 mRNA expression. (A) Expression 
of miR-214-3p in Nox2–/– or WT Tregs (n 
= 6). (B and C) CCR4 and CCR8 mRNA 
expression in Jurkat T cells transfected 
with miR-214-3p mimetic or inhibitor. 
Some cells were treated with the Nox2 
inhibitor gp91ds-tat (30 μM) for 24 
hours. Control cells were transfected 
with miR-negative control and incu-
bated with sc-tat for 24 hours. Graphs 
represent 2 independent experiments. 
(D–F) Levels of miR-214-3p and mRNA 
coding for CCR4 and CCR8 in Jurkat T 
cells incubated 24 hours with PEG-SOD 
(20 IU/ml) and PEG-catalase (300 IU/
ml). Graphs represent 3 independent 
experiments. (G–I) Reporter assay using 
CCR4, CCR4 untranslated region, and 
CCR8 constructs. Graphs represent 2 
independent experiments. Data are 
shown as mean ± SEM. *P < 0.05 for 
indicated comparisons, Mann-Whitney 
2-tailed t test in A, D–F, and H and 
Kruskal-Wallis followed by Dunn’s post 
test in B, C, G, and I.
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We did not see differences in CD4+ T cell infiltration between allografts transplanted into Nox2fl/fl and 
Nox2fl/flFoxP3Cre+mice. This response differs from the pattern of  T cell infiltration in a model of  ANGII- 
induced cardiac remodeling, in which Nox2-deficient mice had a decrease in both CD4+ and CD8+ Teffs (17). 
These differences could be attributed to the distinct importance of  CD4+ and CD8+ cells in different animal 
models. In fact, cytotoxic CD8+ T cell responses against mismatched MHC class I alloantigen are the princi-
pal arm of the cellular response against the transplanted organ (42), whereas cardiac remodeling is modulated 
mainly by CD4+ T cells producing IL-17 (43).
Nox2-deficient Tregs express higher levels of  CCR4 and CCR8, but other chemokine receptors were not 
affected (CCR2, CCR7, CCR6, and CXCR4; Supplemental Figure 7, A and B). Therefore, the presence of  
CCL1 and CCL22 in the heart transplant microenvironment increases the potential therapeutic effects of  
Nox2-deficient Tregs in this context. Because Nox2 deletion does not reduce the expression of  other chemo-
kine receptors, other disease contexts where CCL1 and CCL22 have a secondary role probably would not be 
negatively affected by Nox2 deletion in Tregs.
In conclusion, we observed that Nox2 deficiency increased the suppressive capacity and chemotaxis of  
Tregs in vitro and in vivo (Supplemental Figure 9). Therefore, Nox2 could be used as a target to potentiate Tregs 
with clinical application.
Methods
Mice and in vivo studies. Nox2fl/flFoxP3Cre+ mice were generated by crossing B6129S-Tg (FoxP3-EGFP/
iCre)1aJbs male mice with Nox2 homozygous floxed female mice (19). Heterotopic heart transplants were 
performed as previously described (44).
ELISA. Troponin-I (High sensitivity mouse cardiac Troponin-I ELISA kit, Life Diagnostics, CTNI-1-
HSP) and IFN-γ (Mouse IFN-γ DuoSet ELISA, R&D Systems, DY485-05) levels were determined by ELISA 
according to manufacturer’s recommendations.
Treg purification. CD4+CD25+ cells were purified from spleens and lymph nodes using a commercial kit 
(Dynabeads FlowComp Mouse CD4+CD25+ Treg, catalog 11463D).
Figure 5. Nox2 expression inversely correlates with expression of FoxP3 and miR 214-3p. Linear correlation between (A) 
FoxP3 mRNA and Treg counts in heart allografts, (B) FoxP3 mRNA and Nox2 mRNA, (C) Nox2 mRNA and Treg counts in 
heart allografts, and (D) miR-214-3p expression and Nox2 mRNA (n = 9) 7 days after transplantation. Values of cycle thresh-
old (2–ΔCT) for miR-214-3p were normalized by miR-let-103; Nox2 and FoxP3 were normalized by GAPDH. The R2 values are 
displayed on the top of each correlation.
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Flow cytometry. Levels of alloantibodies in plasma and single-cell analyses of heart allograft digests were 
determined in a LSRFORTESSA flow cytometer (BD Biosciences) and analyzed using FlowJo software 9.7.5. 
Superoxide production was estimated using 10 μM dihydroethidium (17).
Quantitative PCR. RNA was extracted using TRIzol Reagent (Thermo Fisher, 1559626). SYBR green real-
time PCR was performed using the ΔΔCt method and GAPDH for normalization. cDNA synthesis and quan-
titative PCR for miR-214-3p and miR-214-5p were done using an miCury LNAtm MiRNA PCR starter kit, 
mmu-miR-214-3p, and mmu-miR-214-5p (Qiagen, product 339320, YKP-MM-YP00204510-YP00204575).
Cell transfection. Jurkat T cells were transfected with MicroRNA mimic miR-214-3p (hsa-miR-214-3, Ther-
mo Fisher, MC12124) or hsa-miR-214-3p miRCURY LNA miRNA Inhibitor (hsa-miR-214-3p miRCURY 
LNA miRNA Inhibitor, Qiagen, YI04105004-ADA) or miRVanatm miR Mimic, Negative Control (Thermo 
Fisher, 4464058) by electroporation (Lonza, VPA-1002).
Statistics. Analyses were performed using GraphPad Prism software v9.0. Comparisons were undertaken 
using Kruskal-Wallis followed by Dunn’s post test or a Mann Whitney 2-tailed t test or 2-way ANOVA fol-
lowed by Bonferroni post test, as appropriate. A Mantel-Cox test was used to compare survival rates. P < 0.05 
was considered significant.
Study approval. All animal procedures were undertaken in accordance with the Guidance on the Opera-
tion of  the Animals (Scientific Procedures) Act, 1986 (UK Home Office), and with institutional ethics approv-
al from King’s College London.
See Supplemental Methods for additional information.
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